Patents by Inventor Mingli ZHAO

Mingli ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal form of tenofovir prodrug, preparation method thereof, and method of use thereof
    Patent number: 9840525
    Abstract: A crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) is provided. Also provided is a preparation method and method of using the crystal form. Specifically, a crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) having an X-ray powder diffraction (XRPD) spectrum including diffraction peaks at 2?±0.20° of 5.08, 12.44, 13.18, 22.37, 23.37 and 28.56 is provided. The crystal form provided herein has high bioavailability, significant efficacy, good stability, high yield and high purity, and contributes to the selection and design of a drug administration route and the determination of process parameters of a pharmaceutical preparation, thereby improving drug production quality.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: December 12, 2017
    Assignee: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Ming Chen, Chengyao Tian, Mingli Zhao, Jun Yu, Baohai Yang, Aifeng Lu
  • CRYSTAL FORM OF TENOFOVIR PRODRUG, PREPARATION METHOD THEREOF, AND METHOD OF USE THEREOF
    Publication number: 20170204125
    Abstract: A crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) is provided. Also provided is a preparation method and method of using the crystal form. Specifically, a crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) having an X-ray powder diffraction (XRPD) spectrum including diffraction peaks at 2?±0.20° of 5.08, 12.44, 13.18, 22.37, 23.37 and 28.56 is provided. The crystal form provided herein has high bioavailability, significant efficacy, good stability, high yield and high purity, and contributes to the selection and design of a drug administration route and the determination of process parameters of a pharmaceutical preparation, thereby improving drug production quality.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 20, 2017
    Inventors: Ming CHEN, Chengyao TIAN, Mingli ZHAO, Jun YU, Baohai YANG, Aifeng LU